Abstract Topics

Click the Theme names below to expand a full list of available topics.

Theme A: β-Amyloid Diseases / A01.a. Disease Mechanisms, Pathophysiology: Abeta aggregation, protein misfolding
Theme A: β-Amyloid Diseases / A01.b. Disease Mechanisms, Pathophysiology: Cell to cell transmission, spreading of pathology, prion-like
Theme A: β-Amyloid Diseases / A01.c. Disease Mechanisms, Pathophysiology: Inflammation
Theme A: β-Amyloid Diseases / A01.d. Disease Mechanisms, Pathophysiology: Synaptic plastcity & synapse pathology
Theme A: β-Amyloid Diseases / A01.e. Disease Mechanisms, Pathophysiology: Cellular signalling, kinases, phosphatases, calcium
Theme A: β-Amyloid Diseases / A01.f. Disease Mechanisms, Pathophysiology: Lysosomes, ubiquitin, proteasome, ER stress, chaperones
Theme A: β-Amyloid Diseases / A01.g. Disease Mechanisms, Pathophysiology: Mitochondrial dysfunction, oxidative damage
Theme A: β-Amyloid Diseases / A01.h. Disease Mechanisms, Pathophysiology: Lipids, lipoproteins and membrane trafficking
Theme A: β-Amyloid Diseases / A01.i. Disease Mechanisms, Pathophysiology: Microglia
Theme A: β-Amyloid Diseases / A01.j. Disease Mechanisms, Pathophysiology: Astroglia
Theme A: β-Amyloid Diseases / A01.k. Disease Mechanisms, Pathophysiology: Neurogenesis
Theme A: β-Amyloid Diseases / A01.l. Disease Mechanisms, Pathophysiology: Vasculature, microbleeds, hypertension, angiogenesis
Theme A: β-Amyloid Diseases / A01.m. Disease Mechanisms, Pathophysiology: Blood-brain barrier
Theme A: β-Amyloid Diseases / A01.n. Disease Mechanisms, Pathophysiology: Metabolism, insulin
Theme A: β-Amyloid Diseases / A01.o. Disease Mechanisms, Pathophysiology: Neural networks, plasticity
Theme A: β-Amyloid Diseases / A01.p. Disease Mechanisms, Pathophysiology: Transcriptional & translational regulation, micro RNAs
Theme A: β-Amyloid Diseases / A01.q. Disease Mechanisms, Pathophysiology: Autophagy, apoptosis, cell death
Theme A: β-Amyloid Diseases / A01.r. Disease Mechanisms, Pathophysiology: Aging
Theme A: β-Amyloid Diseases / A01.s. Disease Mechanisms, Pathophysiology: Microbiome
Theme A: β-Amyloid Diseases / A01.t. Disease Mechanisms, Pathophysiology: Cholinergic
Theme A: β-Amyloid Diseases / A02.a. Therapeutic Targets, Mechanisms for Treatment: Abeta, truncated & pGlu-Abeta
Theme A: β-Amyloid Diseases / A02.b. Therapeutic Targets, Mechanisms for Treatment: Immunotherapy
Theme A: β-Amyloid Diseases / A02.c. Therapeutic Targets, Mechanisms for Treatment: Secretases, proteases
Theme A: β-Amyloid Diseases / A02.d. Therapeutic Targets, Mechanisms for Treatment: Kinases, other enzymes
Theme A: β-Amyloid Diseases / A02.e. Therapeutic Targets, Mechanisms for Treatment: Neurotransmitters & receptor-based
Theme A: β-Amyloid Diseases / A02.f. Therapeutic Targets, Mechanisms for Treatment: ApoE & lipoprotein-based
Theme A: β-Amyloid Diseases / A02.g. Therapeutic Targets, Mechanisms for Treatment: Anti-inflammatory
Theme A: β-Amyloid Diseases / A02.h. Therapeutic Targets, Mechanisms for Treatment: Anti-oxidants
Theme A: β-Amyloid Diseases / A02.i. Therapeutic Targets, Mechanisms for Treatment: Neurotrophic, synaptic plasticity, repair, regenerative medicine
Theme A: β-Amyloid Diseases / A02.j. Therapeutic Targets, Mechanisms for Treatment: Protein aggregation, misfolding, chaperones
Theme A: β-Amyloid Diseases / A02.k. Therapeutic Targets, Mechanisms for Treatment: TREM2
Theme A: β-Amyloid Diseases / A02.l. Therapeutic Targets, Mechanisms for Treatment: CD33
Theme A: β-Amyloid Diseases / A02.m. Therapeutic Targets, Mechanisms for Treatment: Microglia
Theme A: β-Amyloid Diseases / A02.n. Therapeutic Targets, Mechanisms for Treatment: Astroglia
Theme A: β-Amyloid Diseases / A02.o. Therapeutic Targets, Mechanisms for Treatment: Gene therapy and gene editing
Theme A: β-Amyloid Diseases / A02.p. Therapeutic Targets, Mechanisms for Treatment: ASO and RNAi
Theme A: β-Amyloid Diseases / A02.r. Therapeutic Targets, Mechanisms for Treatment: Other

Theme A: β-Amyloid Diseases / A03.a. Drug Development, Clinical Trials: Immunotherapy
Theme A: β-Amyloid Diseases / A03.c. Drug Development, Clinical Trials: Amyloid clearance
Theme A: β-Amyloid Diseases / A03.d. Drug Development, Clinical Trials: Secretase inhibitors & modulators
Theme A: β-Amyloid Diseases / A03.e. Drug Development, Clinical Trials: Aggregation inhibitors
Theme A: β-Amyloid Diseases / A03.f. Drug Development, Clinical Trials: Neuroprotective & mitochondrial compounds
Theme A: β-Amyloid Diseases / A03.g. Drug Development, Clinical Trials: Neurotransmitter-based modulators
Theme A: β-Amyloid Diseases / A03.k. Drug Development, Clinical Trials: Transcranial magnetic stimulation
Theme A: β-Amyloid Diseases / A03.l. Drug Development, Clinical Trials: Medicinal chemistry approaches, drug repurposing
Theme A: β-Amyloid Diseases / A03.o. Drug Development, Clinical Trials:New clinical trial designs; Simulation of progress-digital twins
Theme A: β-Amyloid Diseases / A03.p. Drug Development, Clinical Trials: Non-pharmacological interventions
Theme A: β-Amyloid Diseases / A04.a. Imaging, Biomarkers, Diagnostics: Structural MRI, MR spectroscopy
Theme A: β-Amyloid Diseases / A04.b. Imaging, Biomarkers, Diagnostics: Functional MRI
Theme A: β-Amyloid Diseases / A04.c. Imaging, Biomarkers, Diagnostics: PET – amyloid
Theme A: β-Amyloid Diseases / A04.d. Imaging, Biomarkers, Diagnostics: PET – glucose
Theme A: β-Amyloid Diseases / A04.e. Imaging, Biomarkers, Diagnostics: PET – other
Theme A: β-Amyloid Diseases / A04.g. Imaging, Biomarkers, Diagnostics: Multimodal imaging
Theme A: β-Amyloid Diseases / A04.h. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers
Theme A: β-Amyloid Diseases / A04.i. Imaging, Biomarkers, Diagnostics: EEG, brain mapping, MEG
Theme A: β-Amyloid Diseases / A04.j. Imaging, Biomarkers, Diagnostics: Cognitive, psychometric & behavioral tests, Digital endpoints, remote testing
Theme A: β-Amyloid Diseases / A04.k. Imaging, Biomarkers, Diagnostics: Other
Theme A: β-Amyloid Diseases / A05.a. Genetics, Epidemiology: Whole genome sequencing
Theme A: β-Amyloid Diseases / A05.b. Genetics, Epidemiology: Disease-causing mutations
Theme A: β-Amyloid Diseases / A05.c. Genetics, Epidemiology: GWAS, genetic associations, susceptibility & protective genes
Theme A: β-Amyloid Diseases / A05.e. Genetics, Epidemiology: Aging
Theme A: β-Amyloid Diseases / A05.f. Genetics, Epidemiology: Environmental risk factors
Theme A: β-Amyloid Diseases / A05.g. Genetics, Epidemiology: Metabolic and cardiovascular
Theme A: β-Amyloid Diseases / A05.h. Genetics, Epidemiology: Infectious and inflammation
Theme A: β-Amyloid Diseases / A05.i. Genetics, Epidemiology: Other
Theme A: β-Amyloid Diseases / A06.a. Cell, Molecular and Systems Biology: APP, APLP, Abeta
Theme A: β-Amyloid Diseases / A06.b. Cell, Molecular and Systems Biology: ApoE
Theme A: β-Amyloid Diseases / A06.c. Cell, Molecular and Systems Biology: Secretases
Theme A: β-Amyloid Diseases / A06.f. Cell, Molecular and Systems Biology: Network biology, connectome, protein-protein interations
Theme A: β-Amyloid Diseases / A06.g. Cell, Molecular and Systems Biology: Metabolomics, transcriptomics, lipidomics, proteomics
Theme A: β-Amyloid Diseases / A06.h. Cell, Molecular and Systems Biology: Epigenetics, histone modification, DNA methylation
Theme A: β-Amyloid Diseases / A06.i. Cell, Molecular and Systems Biology: Other
Theme A: β-Amyloid Diseases / A07.a. Animal Models: Transgenic rodents
Theme A: β-Amyloid Diseases / A07.b. Animal Models: Primates, naturally occuring models and brain organoids
Theme B: Taupathies / B01.a. Disease Mechanisms, Pathophysiology: Tau aggregation, phophorylation, acetylation & modifications
Theme B: Taupathies / B01.b. Disease Mechanisms, Pathophysiology: Cell to cell transmission, spreading of pathology, prion-like
Theme B: Taupathies / B01.c. Disease Mechanisms, Pathophysiology: Inflammation
Theme B: Taupathies / B01.d. Disease Mechanisms, Pathophysiology: Synapse pathology
Theme B: Taupathies / B01.e. Disease Mechanisms, Pathophysiology: Cellular signalling, kinases, phosphatases, calcium
Theme B: Taupathies / B01.f. Disease Mechanisms, Pathophysiology: Lysosomes, ubiquitin, proteasome, ER stress
Theme B: Taupathies / B01.g. Disease Mechanisms, Pathophysiology: Mitochondrial dysfunction, oxidative damage

Theme B: Taupathies / B01.i. Disease Mechanisms, Pathophysiology: Microglia
Theme B: Taupathies / B01.j. Disease Mechanisms, Pathophysiology: Astroglia
Theme B: Taupathies / B01.m. Disease Mechanisms, Pathophysiology: Blood-brain barrier
Theme B: Taupathies / B01.n. Disease Mechanisms, Pathophysiology: Metabolism, insulin
Theme B: Taupathies / B01.o. Disease Mechanisms, Pathophysiology: Neural networks & plasticity
Theme B: Taupathies / B01.p. Disease Mechanisms, Pathophysiology: transcriptional & translational regulation, micro RNAs
Theme B: Taupathies / B01.q. Disease Mechanisms, Pathophysiology: Autophagy, apoptosis, cell death
Theme B: Taupathies / B01.s. Disease Mechanisms, Pathophysiology: Aging
Theme B: Taupathies / B01.u. Disease Mechanisms, Pathophysiology: Other
Theme B: Taupathies / B02.a. Therapeutic Targets, Mechanisms for Treatment: Tau, phosphorylation, truncation
Theme B: Taupathies / B02.b. Therapeutic Targets, Mechanisms for Treatment: Immunotherapy
Theme B: Taupathies / B02.c. Therapeutic Targets, Mechanisms for Treatment: Kinases, phosphatases, other enzymes
Theme B: Taupathies / B02.d. Therapeutic Targets, Mechanisms for Treatment: Neurotransmitters & receptor-based
Theme B: Taupathies / B02.e. Therapeutic Targets, Mechanisms for Treatment: Anti-inflammatory
Theme B: Taupathies / B02.h. Therapeutic Targets, Mechanisms for Treatment: Protein aggregation, NFT, misfolding, chaperones
Theme B: Taupathies / B02.i. Therapeutic Targets, Mechanisms for Treatment: Gene and RNAi therapy
Theme B: Taupathies / B02.j. Therapeutic Targets, Mechanisms for Treatment: Microglia
Theme B: Taupathies / B02.m. Therapeutic Targets, Mechanisms for Treatment: Other
Theme B: Taupathies / B03.a. Drug Development, Clinical Trials: Immunotherapy
Theme B: Taupathies / B03.c. Drug Development, Clinical Trials: tau clearance
Theme B: Taupathies / B03.e. Drug Development, Clinical Trials: Aggregation inhibitors
Theme B: Taupathies / B03.m. Drug Development, Clinical Trials: New clinical trial designs; Simulation of progress-digital twins
Theme B: Taupathies / B04.a. Imaging, Biomarkers, Diagnostics: Structural MRI, MR spectroscopy
Theme B: Taupathies / B04.c. Imaging, Biomarkers, Diagnostics: PET – tau
Theme B: Taupathies / B04.d. Imaging, Biomarkers, Diagnostics: PET – glucose
Theme B: Taupathies / B04.g. Imaging, Biomarkers, Diagnostics: Multimodal imaging
Theme B: Taupathies / B04.h. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers
Theme B: Taupathies / B04.i. Imaging, Biomarkers, Diagnostics: EEG, brain mapping, MEG
Theme B: Taupathies / B04.j. Imaging, Biomarkers, Diagnostics: Cognitive, psychometric & behavioral tests, Digital endpoints, remote testing
Theme B: Taupathies / B04.k. Imaging, Biomarkers, Diagnostics: Other
Theme B: Taupathies / B05.g. Genetics, Epidemiology: Other
Theme B: Taupathies / B06.a. Cell, Molecular and Systems Biology: Tau, tau isoforms
Theme B: Taupathies / B06.d. Cell, Molecular and Systems Biology: Growth factors, synaptic plasticity
Theme B: Taupathies / B06.f. Cell, Molecular and Systems Biology: Network biology, connectome, protein-protein interations
Theme B: Taupathies / B06.g. Cell, Molecular and Systems Biology: Metabolomics, transcriptomics, lipidomics, proteomics
Theme B: Taupathies / B07.a. Animal Models: Transgenic rodents
Theme B: Taupathies / B07.b. Animal Models: Primates, naturally occuring models and brain organoids
Theme C: α-Synucleinopathies / C01.a. Disease Mechanisms, Pathophysiology: a-synuclein aggregation
Theme C: α-Synucleinopathies / C01.b. Disease Mechanisms, Pathophysiology: LRKK2, parkin, PINK1, DJ-1
Theme C: α-Synucleinopathies / C01.c. Disease Mechanisms, Pathophysiology: Cell to cell transmission, spreading of pathology, prion-like
Theme C: α-Synucleinopathies / C01.d. Disease Mechanisms, Pathophysiology: Autophagy, lysosomes, ubiquitin, proteasome
Theme C: α-Synucleinopathies / C01.e. Disease Mechanisms, Pathophysiology: Lipids, lipoproteins and membrane trafficking
Theme C: α-Synucleinopathies / C01.f. Disease Mechanisms, Pathophysiology: Inflammation
Theme C: α-Synucleinopathies / C01.g. Disease Mechanisms, Pathophysiology: Microglia
Theme C: α-Synucleinopathies / C01.h. Disease Mechanisms, Pathophysiology: Astroglia

Theme C: α-Synucleinopathies / C01.i. Disease Mechanisms, Pathophysiology: Cellular signalling, kinases, phosphatases, calcium
Theme C: α-Synucleinopathies / C01.i. Disease Mechanisms, Pathophysiology: Mitochondrial dysfunction, oxidative damage
Theme C: α-Synucleinopathies / C01.k. Disease Mechanisms, Pathophysiology: Synapse pathology, neural networks, plasticity, neurogenesis
Theme C: α-Synucleinopathies / C01.l. Disease Mechanisms, Pathophysiology: Transcriptional & translational regulation, micro RNAs
Theme C: α-Synucleinopathies / C01.n. Disease Mechanisms, Pathophysiology: Protein aggregation, misfolding, chaperones
Theme C: α-Synucleinopathies / C01.o. Disease Mechanisms, Pathophysiology: Metal ions
Theme C: α-Synucleinopathies / C01.p. Disease Mechanisms, Pathophysiology: Modeling of disease progression
Theme C: α-Synucleinopathies / C01.q. Disease Mechanisms, Pathophysiology: Other
Theme C: α-Synucleinopathies / C02.a. Therapeutic Targets, Mechanisms for Treatment: a-synuclein
Theme C: α-Synucleinopathies / C02.b. Therapeutic Targets, Mechanisms for Treatment: Immunotherapy
Theme C: α-Synucleinopathies / C02.c. Therapeutic Targets, Mechanisms for Treatment: Kinases, other enzymes
Theme C: α-Synucleinopathies / C02.d. Therapeutic Targets, Mechanisms for Treatment: Dopamine, Acetylcholine, neurotransmitters
Theme C: α-Synucleinopathies / C02.e. Therapeutic Targets, Mechanisms for Treatment: Cell transplantation
Theme C: α-Synucleinopathies / C02.g. Therapeutic Targets, Mechanisms for Treatment: Anti-inflammatory, anti-oxidant
Theme C: α-Synucleinopathies / C02.h. Therapeutic Targets, Mechanisms for Treatment: Microglia
Theme C: α-Synucleinopathies / C02.i. Therapeutic Targets, Mechanisms for Treatment:Astroglia
Theme C: α-Synucleinopathies / C02.j. Therapeutic Targets, Mechanisms for Treatment: Protein aggregation, misfolding, chaperones
Theme C: α-Synucleinopathies / C02.k. Therapeutic Targets, Mechanisms for Treatment: Gene therapy and gene editing
Theme C: α-Synucleinopathies / C02.l. Therapeutic Targets, Mechanisms for Treatment: ASO and RNAi
Theme C: α-Synucleinopathies / C02.m. Therapeutic Targets, Mechanisms for Treatment: neurogenesis and iPSC
Theme C: α-Synucleinopathies / C02.n. Therapeutic Targets, Mechanisms for Treatment: Other
Theme C: α-Synucleinopathies / C03.a. Drug Development, Clinical Trials: Immunotherapy
Theme C: α-Synucleinopathies / C03.b. Drug Development, Clinical Trials: Vitamins, antioxidants, neuroprotective compounds
Theme C: α-Synucleinopathies / C03.c. Drug Development, Clinical Trials: Neurotransmitter- and receptor based modulators
Theme C: α-Synucleinopathies / C03.e. Drug Development, Clinical Trials: Aggregation inhibitors
Theme C: α-Synucleinopathies / C03.f. Drug Development, Clinical Trials: Enzyme modulators
Theme C: α-Synucleinopathies / C03.h. Drug Development, Clinical Trials: Drug delivery systems
Theme C: α-Synucleinopathies / C03.i. Drug Development, Clinical Trials: Non-pharmacological interventions, neurosurgery
Theme C: α-Synucleinopathies / C04.a. Imaging, Biomarkers, Diagnostics: Structural MRI, MR spectroscopy
Theme C: α-Synucleinopathies / C04.b. Imaging, Biomarkers, Diagnostics: Functional MRI
Theme C: α-Synucleinopathies / C04.c. Imaging, Biomarkers, Diagnostics: PET
Theme C: α-Synucleinopathies / C04.d. Imaging, Biomarkers, Diagnostics: SPECT
Theme C: α-Synucleinopathies / C04.e. Imaging, Biomarkers, Diagnostics: Multimodal imaging
Theme C: α-Synucleinopathies / C04.f. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers
Theme C: α-Synucleinopathies / C04.g. Imaging, Biomarkers, Diagnostics: EEG, brain mapping, MEG
Theme C: α-Synucleinopathies / C04.h. Imaging, Biomarkers, Diagnostics: Cognitive, psychometric, behavioral and motor tests
Theme C: α-Synucleinopathies / C04.j. Imaging, Biomarkers, Diagnostics: Other
Theme C: α-Synucleinopathies / C05.a. Genetics, Epidemiology: Whole genome sequencing
Theme C: α-Synucleinopathies / C05.b. Genetics, Epidemiology: Disease-causing mutations
Theme C: α-Synucleinopathies / C05.c. Genetics, Epidemiology: GWAS, genetic associations, susceptibility & protective genes
Theme C: α-Synucleinopathies / C05.d. Genetics, Epidemiology: Aging
Theme C: α-Synucleinopathies / C05.g. Genetics, Epidemiology: Other
Theme C: α-Synucleinopathies / C06.a. Cell, Molecular and Systems Biology: a-synuclein

Theme C: α-Synucleinopathies / C06.b. Cell, Molecular and Systems Biology: LRKK2, parkin, PINK1, DJ-1 and other PD realted genes
Theme C: α-Synucleinopathies / C06.e. Cell, Molecular and Systems Biology: Network biology, connectome, protein-protein interations
Theme C: α-Synucleinopathies / C06.f. Cell, Molecular and Systems Biology: Metabolomics, transcriptomics, lipidomics, proteomics
Theme C: α-Synucleinopathies / C06.g. Cell, Molecular and Systems Biology: Epigenetics, histone modification, DNA methylation
Theme C: α-Synucleinopathies / C06.h. Cell, Molecular and Systems Biology: Other
Theme C: α-Synucleinopathies / C07.a. Animal Models: Transgenic rodents
Theme C: α-Synucleinopathies / C07.b. Animal Models: Primates, naturally occuring models and brain organoids
Theme D: TDP43, TMEM106B and C9orf72-Related Diseases / D01. Disease Mechanisms, Pathophysiology
Theme D: TDP43, TMEM106B and C9orf72-Related Diseases / D02. Therapeutic Targets, Mechanisms for Treatment
Theme D: TDP43, TMEM106B and C9orf72-Related Diseases / D04. Imaging, Biomarkers, Diagnostics
Theme D: TDP43, TMEM106B and C9orf72-Related Diseases / D05. Genetics, Epidemiology
Theme D: TDP43, TMEM106B and C9orf72-Related Diseases / D06. Cell, Molecular and Systems Biology
Theme D: TDP43, TMEM106B and C9orf72-Related Diseases / D07. Animal Models
Theme E : Vascular Diseases / E01. Disease Mechanisms, Pathophysiology
Theme E : Vascular Diseases / E02. Therapeutic Targets, Mechanisms for Treatment
Theme E : Vascular Diseases / E04. Imaging, Biomarkers, Diagnostics
Theme E : Vascular Diseases / E05. Genetics, Epidemiology
Theme E : Vascular Diseases / E06. Cell, Molecular and Systems Biology
Theme E : Vascular Diseases / E07. Animal Models
Theme F: Prion Diseases / F01. Disease Mechanisms, Pathophysiology
Theme F: Prion Diseases / F02. Therapeutic Targets, Mechanisms for Treatment
Theme F: Prion Diseases / F04. Imaging, Biomarkers, Diagnostics
Theme G: Huntington\’s and Other Neurodegenerative Diseases / G01. Disease Mechanisms, Pathophysiology
Theme G: Huntington\’s and Other Neurodegenerative Diseases / G02. Therapeutic Targets, Mechanisms for Treatment
Theme G: Huntington\’s and Other Neurodegenerative Diseases / G03. Drug Development, Clinical Trials
Theme G: Huntington\’s and Other Neurodegenerative Diseases / G04. Imaging, Biomarkers, Diagnostics
Theme G: Huntington\’s and Other Neurodegenerative Diseases / G05. Genetics, Epidemiology
Theme G: Huntington\’s and Other Neurodegenerative Diseases / G06. Cell, Molecular and Systems Biology
Theme G: Huntington\’s and Other Neurodegenerative Diseases / G07. Animal Models
Theme H: Demyelinating Diseases / H02. Therapeutic Targets, Mechanisms for Treatment
Theme H: Demyelinating Diseases / H04. Imaging, Biomarkers, Diagnostics
Theme H: Demyelinating Diseases / H07. Animal Models
Theme I: Lysosomal Storage Diseases / I01. Disease Mechanisms, Pathophysiology
Theme I: Lysosomal Storage Diseases / I02. Therapeutic Targets, Mechanisms for Treatment
Theme I: Lysosomal Storage Diseases / I07. Animal Models and brain organoids
Theme J: Psychiatric Symptoms in Neurodegenerative Diseases / J01. Disease Mechanisms, Pathophysiology
Theme J: Psychiatric Symptoms in Neurodegenerative Diseases / J02. Therapeutic Targets, Mechanisms for Treatment
Theme J: Psychiatric Symptoms in Neurodegenerative Diseases / J03. Drug Development, Clinical Trials
Theme J: Psychiatric Symptoms in Neurodegenerative Diseases / J04. Imaging, Biomarkers, Diagnostics
Theme J: Psychiatric Symptoms in Neurodegenerative Diseases / J05. Genetics, Epidemiology
Theme J: Psychiatric Symptoms in Neurodegenerative Diseases / J06. Cell, Molecular and Systems Biology
Theme J: Psychiatric Symptoms in Neurodegenerative Diseases / J07. Animal Models
Theme K: Patient Care and Support / K01.a. Dementia and Cognitive Dyfunction: Caregiver support
Theme K: Patient Care and Support / K01.b. Dementia and Cognitive Dyfunction: Mobile applications, social networks

Theme K: Patient Care and Support / K01.c. Dementia and Cognitive Dyfunction: Cognitive training
Theme K: Patient Care and Support / K01.e. Dementia and Cognitive Dyfunction: Support devices & monitoring
Theme K: Patient Care and Support / K01.f. Dementia and Cognitive Dyfunction: Quality of life
Theme K: Patient Care and Support / K01.h. Dementia and Cognitive Dyfunction: Behavioral & psychiatric symptoms
Theme K: Patient Care and Support / K01.j. Dementia and Cognitive Dyfunction: Other
Theme K: Patient Care and Support / K02.a. Movement Disorders: Caregiver support
Theme K: Patient Care and Support / K02.c. Movement Disorders: Motor coordination & exercise
Theme K: Patient Care and Support / K02.d. Movement Disorders: Support devices & monitoring
Theme K: Patient Care and Support / K02.f. Movement Disorders: Quality of life
Theme K: Patient Care and Support / K02.g. Movement Disorders: Behavioral & psychiatric symptoms
Theme K: Patient Care and Support / K02.h. Movement Disorders: Other
Theme L: COVID-19: Impact on Brain Neurodegenerative Diseases / L01a. Neuropathology of Covid-19
Theme L: COVID-19: Impact on Brain Neurodegenerative Diseases / L01b. Neuroimaging of Covid-19
Theme L: COVID-19: Impact on Brain Neurodegenerative Diseases / L01c. Neurological manifestations of Covid-19
Theme L: COVID-19: Impact on Brain Neurodegenerative Diseases / L01d. Comorbidity of Neurodegeneration with Covid-19
Theme L: COVID-19: Impact on Brain Neurodegenerative Diseases / L01f. CNS invasion of SARS-CoV2
Theme L: COVID-19: Impact on Brain Neurodegenerative Diseases / L01g. Epidemiology of Covid-19 in Patients with Neurodegenerative Diseases

ABSTRACT SUBMISSION